Impact of serological activity on flare following clinically inactive disease and remission in childhood-onset systemic lupus erythematosus
Authors' conclusion
SA during remission increases the odds of flare, but SA at CID does not.
Study context
- Population
- Children with childhood-onset SLE from three paediatric rheumatology referral centres
- Participants
- 124 children
- Exposure
- Serological activity vs no serological activity at clinically inactive disease (CID) and during remission
- Outcome
- Moderate-to-severe flare after attainment of CID and after remission, and its association with serological activity
Methodological detailsmulticentre, longitudinal
- Multicentre
- Longitudinal
Main finding
As reported in the abstract
Flare after CID (before remission)
Moderate-to-severe flare before remission among patients with CID
24
20.7%
Previous proliferative LN, OR for flare after CID (P: 0.01)
10.2
Autoimmune haemolytic anaemia, OR for flare after CID (P: 0.02)
6.4
Observational data: associations, not effects.
Further findings
Flare after remission · median of 18 months after remission
- Patients with flare after remission
- 21 (19.6%)
- Hypocomplementemia during remission, OR for flare (P: 0.02)
- 9.8
- Daily HCQ dose <5 mg/kg during remission, OR for flare (P: 0.02)
- 5.8
Rate of serological activity
- Serological activity (SA) at onset
- 89.5%
- SA at first CID
- 43.3%
- SA at remission
- 12.1%
Original publication
Impact of serological activity on flare following clinically inactive disease and remission in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford). Published 4 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →